• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Cystoid Macular Edema - Pipeline Review, Q1 2011 - Product Image

Cystoid Macular Edema - Pipeline Review, Q1 2011

  • ID: 1590112
  • March 2011
  • 25 pages
  • Global Markets Direct

Cystoid Macular Edema - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Cystoid Macular Edema - Pipeline Review, Q1 2011', provides an overview of the Cystoid Macular Edema therapeutic pipeline. This report provides information on the therapeutic development for Cystoid Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystoid Macular Edema. 'Cystoid Macular Edema - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cystoid Macular Edema.
- A review of the Cystoid Macular Edema products under development by companies and READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cystoid Macular Edema Overview
Therapeutics Development
An Overview of Pipeline Products for Cystoid Macular Edema
Cystoid Macular Edema Therapeutics under Development by Companies
Cystoid Macular Edema Therapeutics under Investigation by Universities/Institutes
Cystoid Macular Edema Therapeutics - Products under Development by Companies
Cystoid Macular Edema Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Cystoid Macular Edema Therapeutics Development
Sanofi-Aventis
Inspire Pharmaceuticals, Inc.
Icon Bioscience, Inc.
Cystoid Macular Edema - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Universities/Institutes
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cystoid Macular Edema - Featured News
Aug 05, 2009: Icon Bioscience Completes Enrollment In Phase I Study Of Novel Ophthalmic Drug Candidate IBI-20089
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Cystoid Macular Edema, Q1 2011
Products under Development for Cystoid Macular Edema – Comparative Analysis, Q1 2011
Sanofi-Aventis, 2011
Inspire Pharmaceuticals, Inc., 2011
Icon Bioscience, Inc., 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011

List of Figures
Number of Products under Development for Cystoid Macular Edema, Q1 2011
Products under Development for Cystoid Macular Edema – Comparative Analysis, Q1 2011
Products under Development by Companies, Q1 2011
Products under Investigation by Universities/Institutes, Q1 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products, Q1 2011
Assessment by Route of Administration, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Assessment by Stage and Molecule Type, Q1 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos